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Abstract 
How much, how often and how fast a drug reaches the brain determine the behavioural and neuroplastic changes associated with the 
addiction process. Despite the critical nature of these variables, the drug addiction field often ignores pharmacokinetic issues, which 
we argue can lead to false conclusions. First, we review the clinical data demonstrating the importance of the speed of drug onset and 
of intermittent patterns of drug intake in psychostimulant drug addiction. This is followed by a review of the preclinical literature 
demonstrating that pharmacokinetic variables play a decisive role in determining behavioural and neurobiological outcomes in animal 
models of addiction. This literature includes recent data highlighting the importance of intermittent, ‘spiking’ brain levels of drug in 
producing an increase in the motivation to take drug over time. Rapid drug onset and intermittent drug exposure both appear to push 
the addiction process forward most effectively. This has significant implications for refining animal models of addiction and for better 
understanding the neuroadaptations that are critical for the disorder. 
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Highlights  
• Drug pharmacokinetics determine neurobehavioural changes linked to addiction 
• The drug addiction field often ignores pharmacokinetic issues 
• Rapid drug onset and intermittent use both facilitate the transition to addiction 
• This has implications for refining animal models of the process of addiction 
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1. Introduction 
Amongst people who use drugs, some keep control over their 
drug use while others develop addiction. What accounts for this 
differential vulnerability? Like any complex disease, “the 
development of addiction depends on the interaction of agent, 
host and environment” (O’Brien, 2008). With this reality, it 
becomes clear that to identify the brain changes that are critical 
to addiction, it is important that we understand how agent, host 
and environment each influence the response to drugs of abuse. 
The roles of the individual and of the environment are studied 
extensively. Much less attention has been paid to characteristics 
of the ‘agent’, such as drug pharmacokinetics. In the context of 
drug addiction, important pharmacokinetic parameters include 
how much drug gets to the brain (achieved dose), how fast drug 
levels rise in the brain (rate of drug onset) and how often they 
rise and fall (intermittency). 
Thirty-five years ago, Robert Post emphasized the importance 
of the temporal dynamics of stimulation by drugs and other 
stimuli in ‘…determining the direction and magnitude of 
adaptive response following repeated presentation’ (Post, 
1980). When considering the response to a drug of abuse or any 
pharmacological agent for that matter, pharmacokinetics 
determine the pharmacodynamics. That is, pharmacokinetics 
govern the ability of drugs to interact with transporters and 
receptors, and to influence intra-cellular signalling cascades. 
The same drug can have markedly different – sometimes 
opposite – effects on brain and behaviour depending on 
whether it is injected intravenously (i.v.), or into the 
intraperitoneal (i.p.) cavity, administered through the skin, 
taken orally or given chronically in a subcutaneous (s.c.) 
osmotic minipump. This is because different routes of drug 
administration produce markedly different pharmacokinetic 
profiles. This is why a drug that can produce addiction when 
smoked or injected can be used to treat addiction when given 
orally (methadone) or in a patch (nicotine). Similarly, 
amphetamine formulated to produce slowly rising and steady-
state levels of drug in the brain is currently used as 
pharmacotherapy for cocaine addiction (Negus and 
Henningfield, 2015). Methadone, nicotine and amphetamine 
are striking examples from the clinical literature showing that 
manipulation of pharmacokinetic variables can fundamentally 
change the behavioural effects of drugs—rather than having 
abuse potential they might actually have therapeutic potential. 
As will be shown below, pharmacokinetics determine all drug 
effects that are relevant to addiction. 
The influence of pharmacokinetics on the response to drugs of 
abuse remains largely unstudied, save for dose. This is in part 
because in the addiction field, it is widely assumed that the 
amount of drug exposure largely determines outcome (Ahmed, 
2012, Benowitz and Henningfield, 1994 and Jonkman et al., 
2012). Some have even suggested the existence of a ‘critical 
level’ of drug exposure beyond which “addiction-causing 
neuropathological processes could be set in motion” (Ahmed, 
2012). Drug pharmacokinetics are often regarded as secondary, 
simply a means to vary the amount of drug reaching the brain. 
This assumption is dangerous. Variation in the pharmacokinetic 
profile of a drug can produce different effects even when the 
same amount of drug reaches the brain. In other words, “how 
fast” and “how often” can be more important than “how much” 
in determining functional outcome. This principle is at the core 
of the present review. The general principles that will be 
discussed apply across drug classes. However, it is not feasible 
to review all drug classes. Opiates, alcohol and nicotine present 
their own specific pharmacokinetic issues and these deserve to 
be reviewed in depth. Here we will focus on cocaine. We do so 
for three principle reasons. First, cocaine can be snorted, 
smoked or injected and these different routes result in very 
different pharmacokinetic profiles. Second, the clinical 
literature emphasizes the importance of pharmacokinetics in 
cocaine addiction (Hatsukami and Fischman, 1996). Third, in 
animal studies, cocaine is most often used as a prototypical 
drug of abuse to investigate the contributions of 
pharmacokinetics to drug response. Thus, here we review the 
evidence showing that in addition to drug dose, the speed of 
drug onset and the intermittency of drug exposure both 
determine brain and behaviour changes that are relevant to 
addiction, particularly cocaine addiction. 
2. Drug pharmacokinetics influence drug addiction liability 
The clinical data are clear; the faster drugs reach the brain, the 
more likely it is that addiction will develop. Drugs of abuse are 
often taken by the i.v., smoked, oral or intranasal routes. The 
route of drug administration determines both how fast (rise 
time) and how much (area under the curve) drug reaches the 
general circulation and ultimately, the brain (see Fig. 1). 
However, rise time can be more predictive of addiction liability 
than other parameters such as area under the curve. Smoking 
and injecting are the two fastest and most efficient methods of 
getting drug into the bloodstream (Cone, 1995, Cone, 
1998 and Evans et al., 1996). Peak venous plasma levels of 
cocaine or radiolabelled cocaine are reached in 2–5 min 
following i.v. injection or smoking, and 30–60 min after 
intranasal administration (Cone, 1998, Javaid et al., 1978, 
Jeffcoat et al., 1989 and Van Dyke et al., 1976). (Of note, peak 
arterial plasma levels of drug are reached earlier than peak 
venous plasma levels, for example time to peak arterial cocaine 
levels after smoking or intravenous injection is 15 s; Evans et 
al., 1996). The oral and intranasal routes result in slower 
absorption rates, which in turn result in lower blood 
concentrations, over a longer period of time (Cone, 
1995 and Cone, 1998). Peak plasma levels of drug correlate 
well in time with the subjective effects of drugs. For a drug like 
cocaine, for example, the maximum self-reported ‘high’ is 
reached 1–5 min after intravenous injection, and 15–20 min 
after intranasal administration (Evans et al., 1996 and Javaid et 
al., 1978). 
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Fig. 1. The pharmacokinetic profiles of plasma cocaine levels in 
humans as a function of the route of drug administration. Plasma 
cocaine levels rise sharply and decline rapidly when cocaine is 
injected intravenously or smoked. In contrast, plasma cocaine levels 
rise and decline more slowly following intranasal or oral 
administration of the drug. Data represent the mean for 10 human 
subjects in each condition. Adapted from Jones (1990). 
Addiction is more likely and more severe in individuals who 
take drugs via rapid routes of drug delivery. For instance, 
addiction to cocaine, amphetamine, methamphetamine, nicotine 
or heroin is more probable in people who consume these drugs 
via smoking or i.v. injection than in individuals who use slower 
routes of drug administration (e.g., the intranasal or transdermal 
routes; Barrio et al., 2001, Budney et al., 1993, Carpenter et al., 
1998, Ferri and Gossop, 1999, Gossop et al., 1992, Gossop et 
al., 1994, Hatsukami and Fischman, 1996, Hughes, 1989, 
Rawson et al., 2007, Van Dyke and Byck, 1982, Volkow and 
Swanson, 2003 and Winger et al., 1992). Compared to 
intranasal drug users, individuals who smoke or inject drugs 
i.v. also use drugs more frequently, for a longer time, spend 
more money on drugs, report a greater loss of control over drug 
taking and are more likely to overdose (Barrio et al., 2001, 
Carpenter et al., 1998, Ferri and Gossop, 1999, Gossop et al., 
1992, Gossop et al., 1994, Hatsukami and Fischman, 1996, 
Hughes, 1989, Rawson et al., 2007, Van Dyke and Byck, 1982, 
Volkow and Swanson, 2003 and Winger et al., 1992). Finally, 
users who smoke or inject drugs have more health-threatening 
patterns of drug use (Carpenter et al., 1998, Ferri and Gossop, 
1999, Gossop et al., 1992, Hatsukami and Fischman, 1996, 
Hughes, 1989, Rawson et al., 2007 and Winger et al., 1992), 
and they suffer more harm, including contracting blood borne 
viruses such as HIV and hepatitis C, experiencing drug-induced 
paranoid psychosis, and dying of an overdose (Brady et al., 
1991, Gossop et al., 1992, Hatsukami and Fischman, 1996, 
Roncero et al., 2012 and Winger et al., 1992). 
The oral route is much slower and therefore carries less 
addiction liability. However, the risk exists and drug 
manufacturers make efforts to reduce the speed of absorption of 
certain potentially addictive medications. For example, 
amphetamine (Adderall), methylphenidate (Ritalin) and 
phenmetrazine (Preludin) are being designed to reduce the 
speed of brain uptake and the ability of users to smoke or inject 
the drugs (Connor and Steingard, 2004 and Spencer et al., 
2006). 
The intermittency of drug use is also a recurrent theme in the 
addiction literature. Systematic research on the temporal 
pattern of drug use in humans is scarce. There are however 
anecdotal reports and general agreement that intermittency of 
intake is a defining feature of psychostimulant drug addiction. 
There appear to be two, possibly independent intermittency 
phenomena. The first is the ‘abstinence period’, which can last 
for days or weeks. The second is the inter-dosing interval 
within a bout of intoxication. Drug users adopt intermittent 
patterns of use, and this is seen both within and between a bout 
of intoxication. The notion of intermittent drug use in addicts, 
particularly for drugs like cocaine, is emphasized in classic 
writings on addiction (Gawin and Kleber, 1986 and O’Brien, 
2001), and is supported by anecdotal reports and observational 
studies primarily involving experienced drug users. For 
example, Ward et al. (1997) state “anecdotal reports from the 
majority of cocaine users in our laboratory indicate that binges 
may last for days, with intervals of heavy cocaine use separated 
by brief breaks in which the user hustles in order to get enough 
money to buy more cocaine”. Similarly, Cohen and Sas (1994) 
studied patterns of cocaine use in addicts in Amsterdam, and 
they report that sustained and high levels of use are “rarely 
maintained” and that “Many users lace their cocaine use career 
with periods of abstention. Such periods may last from a week 
to several months.” This suggests that cocaine addicts are 
unlikely to maintain continuously high brain levels of drug over 
extended periods. Addicts do engage in drug binges, where 
drug is taken at a high frequency during a bout lasting from 
hours to days. For instance, craving for cocaine is reported to 
be highest shortly after intake of the drug (Jaffe et al., 
1989 and O’Brien et al., 1992). This can favour the transition 
towards a binge pattern of administration and addiction 
(Gawin, 1991). However, even within a binge, the pattern of 
use appears to be intermittent. A recent study on this issue 
suggests that experienced users wait, on average, well over an 
hour between cocaine uses within a binge (Beveridge et al., 
2012). Cocaine has a half-life of ∼40 min (Javaid et al., 1983). 
This suggests that during a binge, blood levels of the drug are 
not maintained at continuously high levels but might rise and 
fall in a spiking pattern (Zimmer et al., 2012). This intermittent 
and spiking pattern of drug levels is thought to promote the 
transition to cocaine addiction (Zimmer et al., 2012). Similarly, 
smoking cigarettes is also thought to be particularly addictive 
because the puff-by-puff inhalation of cigarette smoke 
produces intermittent and fast-rising spikes in brain levels of 
nicotine (Russell and Feyerabend, 1978) and of other 
components of tobacco smoke thought to enhance the addictive 
properties of nicotine (Berlin and Anthenelli, 2001). 
3. Preclinical studies show that drug pharmacokinetics 
determine brain and behaviour effects relevant to addiction 
Clinical studies point to the very important role of 
pharmacokinetic variables in drug addiction liability—in 
particular the rapidity of drug onset and the intermittency of 
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drug exposure. The clinical data are correlational, but they 
make clear predictions that can be tested empirically in 
animals. Animal studies provide greater opportunities to study 
how pharmacokinetic variables influence the response to drugs. 
Here we review evidence from such studies indicating the 
powerful influence of pharmacokinetic variables on drug 
effects relevant to addiction. We begin by presenting simpler 
models, in which pharmacokinetic variables are limited to dose 
and route of administration. We then lead through to self-
administration studies, where there are challenging interactions 
to be considered. 
Until recently, the great majority of animal studies on the 
response to drugs used experimenter-administered, i.p. 
injections, and much has been learned from these experiments. 
Fig. 2 illustrates the pharmacokinetic profiles of an i.p. versus 
an i.v. injection of cocaine. Comparing Fig. 1 and Fig. 2 
suggests that an i.p. injection produces a pharmacokinetic 
profile closest to that produced by intranasal or oral drug 
administration in humans. Though drug absorption is slower 
from the i.p. cavity, a vast literature shows that i.p. drug 
injections are nonetheless powerful in producing behavioural 
and neurobiological effects. This literature also highlights the 
importance of intermittent drug exposure followed by a 
withdrawal period in promoting sensitization-like changes in 
brain and behaviour (Vezina et al., 2007). Thus, studies using 
i.p. drug injections laid the groundwork for understanding how 
the temporal pattern of drug exposure influences the response 
to drug. For instance, intermittent exposure to drug achieved 
via experimenter-administered i.p. injections of cocaine 
(Downs and Eddy, 1932, Post, 1980, Post and Rose, 1976, 
Reith et al., 1987 and Stewart and Badiani, 1993) or nicotine 
(Baker et al., 2013 and Di Chiara, 2000) more readily induces 
sensitization to the psychomotor activating effect of these 
drugs, while continuous infusion produces tolerance to this 
effect. 
 
Fig. 2. The pharmacokinetic profiles of plasma cocaine levels in rats 
following intravenous (i.v.) and intraperitoneal (i.p.) administration. 
Plasma cocaine levels rise sharply and decline rapidly following an 
intravenous injection. In contrast, plasma cocaine levels rise and 
decline more slowly following an intraperitoneal injection of the drug. 
Note that following intravenous injection, cocaine concentrations in 
plasma rise rapidly and reach Cmax within the first 5 min, which was 
the earliest sampling interval in this experiment. Adapted from Pan et 
al. (1991). 
Psychomotor sensitization refers to a gradual and progressive 
increase in the locomotor response to the same or lower doses 
of a drug with repeated treatment (Eikelboom and Stewart, 
1982, Kuczenski and Segal, 1988, Robinson and Becker, 
1986 and Siegel, 1977), and is also characterized by a faster 
onset of locomotor activation in response to drug 
administration (Carey and Gui, 1998 and Segal et al., 1981). 
The ability of drugs to produce psychomotor sensitization 
might reflect their ability to sensitize reward and motivational 
processes, thus promoting drug use and addiction (Robinson 
and Berridge, 1993, Robinson and Berridge, 2000 and Vezina, 
2004). For instance, intermittent i.p. injections of amphetamine, 
morphine, or cocaine produce sensitization to the rewarding 
effects of these drugs, as measured by the conditioned place 
preference test (Lett, 1989). Intermittent i.p. injections of 
amphetamine, cocaine or nicotine also increase the 
susceptibility to subsequently initiate voluntary self-
administration of these drugs (Horger et al., 1990, Neugebauer 
et al., 2014, Piazza et al., 1990, Pierre and Vezina, 
1997 and Pierre and Vezina, 1998) and increase the work 
output animals will emit to obtain drug (Mendrek et al., 1998, 
Neugebauer et al., 2014 and Vezina et al., 2002). 
The intermittency of drug exposure also determines the nature 
and direction of cocaine-evoked neuroadaptations within the 
dopamine system—a system that is fundamental to the 
reinforcing effects of psychostimulant drugs. Intermittent, once 
a day i.p. cocaine injections enhance cocaine-induced inhibition 
of striatal dopamine reuptake (Izenwasser and Cox, 1990), 
while continuous infusion of the drug over a 24-h period 
attenuates the effects of cocaine on reuptake (Izenwasser and 
Cox, 1992). Intermittent cocaine administration also produces 
functional subsensitivity of D2 autoreceptors that modulate 
dopamine release, while continuous cocaine administration 
produces D2 autoreceptor supersensitivity (Jones et al., 1996). 
Within an intermittent, i.p. dosing schedule, the time interval 
between injections is also important. For instance, even when 
the total daily dose of cocaine is held constant, injecting the 
drug at short intervals preferentially evokes dopamine receptor 
upregulation within cortical and striatal brain regions 
(Unterwald et al., 2001). This suggests that the frequency of 
drug-evoked changes in extracellular dopamine levels, and by 
implication, the frequency of dopamine receptor activation, 
determines the long-term consequences of cocaine exposure 
(Unterwald et al., 2001). 
Another model used to study drug effects relevant to addiction 
is the conditioned place preference paradigm. It measures the 
conditioned reinforcing properties of a physical environment 
that has been paired with the effects of a drug. In this paradigm, 
dose is generally the only pharmacokinetic variable studied 
(and this work shows that the ability of drugs like cocaine to 
produce a conditioned place preference is dose-dependent; 
Spyraki et al., 1982). A notable exception is work done by 
Nomikos and Spyraki. They compared the i.v. and i.p. routes 
and report that across a range of doses, conditioned place 
preference to i.v. cocaine requires fewer conditioning sessions, 
Time  (min)
C
o
ca
in
e
  c
o
n
ce
n
tr
a
tio
n
  (
µ
M
)
ip  plasma
iv  plasma
40
30
20
10
0
0 40 80 120 160
! 6!
is less susceptible to procedural factors, and is of greater 
magnitude than conditioning with i.p. cocaine (Nomikos and 
Spyraki, 1988). The same group also reports that the dopamine 
D2/3 antagonist haloperidol disrupts conditioned place 
preference evoked by i.v. but not i.p. cocaine (Spyraki et al., 
1987). This was one of the first findings to suggest that the 
neurobiology mediating the reinforcing effects of cocaine 
varies as a function of the route of drug administration. The 
speed of drug onset differs markedly when cocaine is injected 
i.p. versus i.v. (Fig. 2). Thus, the work of Spyraki and 
colleagues recalls what the clinical literature has taught; the 
speed of drug onset is critical in determining outcome. 
The i.p. route cannot be used to manipulate the speed of drug 
onset; however, the i.v. route can. In a series of studies in rats, 
we have used experimenter-administered i.v. drug injections to 
study the effects of variation in the speed of drug onset on the 
susceptibility to develop psychomotor sensitization. The 
findings concord with the clinical literature. They show that the 
speed of drug onset determines behavioural plasticity. These 
studies using experimenter-administered i.v. injections of 
cocaine are also important in that they bridge the gap between 
the literature using i.p. drug injections (the great majority of the 
work on psychomotor sensitization and conditioned place 
preference) and the literature using animal models of i.v. drug 
self-administration. In these studies, we varied the speed of 
drug onset by varying the speed of i.v. injection between 3 and 
100 s. Across this range, there is no effect of injection speed on 
the acute locomotor response to cocaine or nicotine (Samaha et 
al., 2002, Samaha et al., 2004 and Samaha et al., 2005). 
However, we found that increasing the speed of cocaine or 
nicotine delivery by as little as 20 s increases the susceptibility 
to psychomotor sensitization (Samaha et al., 2002, Samaha et 
al., 2004 and Samaha et al., 2005). A first series of experiments 
showed that across a range of doses (0.5–2 mg/kg/infusion), 
and using both rotational behaviour in rats with a unilateral 6-
hydroxydopamine lesion (a manipulation which destroys 
nigrostriatal dopamine neurons) and locomotor activity in 
neurologically intact rats as indices of psychomotor activation, 
rapid i.v. injections of cocaine (3–16 versus 25–100 s) promote 
the development of psychomotor sensitization (Samaha et al., 
2002). Next, we showed that psychomotor sensitization to a 
single i.v. injection of cocaine developed when cocaine was 
injected rapidly (over 5 s) but not when it was injected more 
slowly (25–100 s; Samaha et al., 2004). Fig. 3 illustrates this 
effect. Finally, we showed that the influence of the speed of 
drug onset also extends to another drug, nicotine. Rapid (5 
versus 25–100 s) i.v. injection also promoted the development 
of psychomotor sensitization to nicotine (Samaha et al., 2005). 
Of course, most studies of psychomotor sensitization use i.p. 
injections of psychostimulant drugs. Intraperitoneal injection 
would result in slower drug absorption relative to a 5-s i.v. 
injection (Fig. 2), but it is nonetheless effective in producing 
psychomotor sensitization. Consistent with this, we found that 
slower i.v. drug injections can still produce sensitization but 
this requires the use of higher doses and repeated exposure 
(Samaha et al., 2002, Samaha et al., 2004 and Samaha et al., 
2005). Thus, the faster cocaine or nicotine are administered, the 
more likely they are to induce behavioural sensitization. A 
clear implication is that even when the route of drug 
administration is held constant, the speed of drug delivery must 
influence the effects of drugs on the brain. 
 
Fig. 3. Increasing the speed of intravenous cocaine delivery facilitates 
the development of psychomotor sensitization and promotes c-fos 
mRNA expression in corticolimbic regions. The panel on the left 
illustrates psychomotor activity averaged over the first 12 min 
following an intravenous injection of 2.0 mg/kg cocaine, delivered by 
an experimenter over 5, 25 or 100 s, on two consecutive days. Data are 
mean ± SEM. Panels on the right show representative densitograms 
illustrating c-fos mRNA levels in the brains of rats injected with 
2.0 mg/kg cocaine at different speeds. Coc, cocaine. s, second. 
Adapted from Samaha et al. (2004). 
Small variations in the speed of cocaine or nicotine onset have 
large effects on the neurobiological impact of these drugs. 
Increasing the speed of drug onset promotes changes in cellular 
activity in mesocorticolimbic structures (Porrino, 1993, 
Samaha et al., 2004 and Samaha et al., 2005; see Fig. 3), 
greater and more immediate increases in heat-producing, 
metabolic activity in the ventral tegmental area and nucleus 
accumbens (Brown and Kiyatkin, 2005), and more immediate 
increases in dopamine transporter blockade (Samaha et al., 
2004) and extracellular dopamine levels (Ferrario et al., 2008) 
in the striatum. With the exception of Porrino (1993), who 
compared i.p. and i.v. injections of cocaine, the speed of drug 
onset was varied by manipulating the speed of i.v. drug 
injection between 4 and 100 s. Pharmacokinetic modelling 
predicts that across these i.v. injection speeds, peak brain 
concentrations of cocaine would not vary, but the rate of rise of 
brain drug levels would (Samaha et al., 2002). Consistent with 
this prediction, this range of injection speeds produces 
differences in the rate of rise of striatal dopamine levels, 
without affecting peak dopamine overflow (Ferrario et al., 
2008 and Zernig, 1997). Similarly, Woolverton and Wang 
(2004) manipulated the speed of i.v. cocaine delivery across an 
even wider range (10–600 s) and found that faster i.v. cocaine 
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injections produce a more rapid onset of dopamine transporter 
occupancy without altering maximum occupancy levels. These 
findings agree with clinical work suggesting that across a range 
of cocaine doses that produce similar plasma levels of drug, 
i.v., smoked or intranasal cocaine produce the same maximum 
levels of dopamine transporter occupancy, while producing 
different subjective effects (Volkow et al., 2000). 
3.1. The effects of pharmacokinetic variables in intravenous 
drug self-administration models 
As a model of drug-taking behaviour, i.v. drug self-
administration in laboratory animals provides a strong 
opportunity to study how dose, speed of drug onset and 
intermittency of drug exposure interact to determine patterns of 
drug use. However, the model also offers considerable 
challenges. The pharmacokinetic issues can become quite 
complicated. Rather than dealing with a single, isolated 
injection, self-administration procedures result in multiple 
infusions, at various time intervals. The pattern of drug taking 
is influenced by summated brain levels, as well as how fast and 
how often these levels rise and fall. Understanding how 
pharmacokinetic variables affect cocaine intake and how 
cumulative cocaine exposure and the kinetics of this exposure 
affect cocaine seeking is critical to the design of animal models 
used in the study of the addiction process. 
3.2. Drug taking (consummatory) versus drug seeking 
(appetitive) responses 
Drug taking and drug seeking responses represent different 
categories of behaviour (i.e., consummatory and appetitive) 
that are likely regulated by different neural mechanisms 
(Roberts et al., 2013). Nonetheless, the sections below 
highlight that pharmacokinetic variables have parallel effects 
on the two response categories. The difference between 
appetitive and consummatory responses is rather obvious in 
humans; the consummatory response (smoking, 
drinking/swallowing, injecting, snorting) is an ingestive act that 
can become ritualistic. Appetitive responses involve more 
varied behaviours that result in gaining access to the drug 
(acquiring money, seeking out suppliers, paying for drug). 
Similarly in a typical operant experiment in which food is used 
as reinforcement, a lever response or nose poke would be 
considered an appetitive response that results, according to a 
defined schedule, in the delivery of a food pellet. The animal 
then has the option of ingesting the food. Pressing a lever and 
eating a food pellet are clearly different response types 
representing the appetitive and consummatory class. This 
distinction is also important in that it shapes experimental 
questions. For instance, identifying the processes an individual 
might use to regulate their intake of free alcohol is quite 
different from determining how much someone might pay for a 
particular bottle of wine. 
In experiments involving animals self-administering drug via 
i.v. catheters, consummatory and appetitive responses are not 
as clearly partitioned. As discussed elsewhere, intravenous drug 
self-administration studies – particularly under a fixed ratio 1 
schedule of reinforcement (one operant response provides one 
drug infusion; FR1) – are a special case wherein the appetitive 
and consummatory responses are in fact necessarily conflated 
(Roberts et al., 2013). Since drug reinforcement is a 
programmed infusion delivered via a catheter, the 
consummatory act is entirely circumvented; there is no external 
stimulus to direct an ingestive behaviour towards (no smoking, 
drinking/swallowing, injecting, snorting). The nose poke or 
lever press becomes not only an appetitive response in the 
traditional operant sense but also a consummatory response that 
controls drug ingestion. 
Whether the rates and patterns of responding exhibited in an 
intravenous drug self-administration experiment are controlled 
by appetitive or consummatory mechanisms will depend, to a 
large extent, on the schedule of reinforcement used. When 
using an FR1 schedule, every response leads to the intake of 
drug, thus every response is a consummatory act (though in 
light of the discussion above, the response might also reflect an 
appetitive process). An FR1 schedule therefore provides an 
opportunity to study the mechanisms that control drug intake. 
Such studies can presumably model specific human drug taking 
patterns and therefore allow the opportunity to study 
phenomena associated with limited versus extended drug 
access and “binges” for example. Below we will discuss how 
dose, speed of injection and intermittency of access affect the 
rates and patterns of cocaine consumption. Finally, we will 
discuss how these same pharmacokinetic variables influence 
appetitive responding, as measured using schedules that require 
an exponential increase in work demand in order to obtain each 
successive reinforcer, thus producing higher rates of operant 
behaviour prior to the delivery of the drug, in particular the 
progressive ratio schedule of drug reinforcement (PR). It could 
well be argued that FR schedules above FR1 also measure 
appetitive responses because they require that several operant 
responses be emitted before delivery of the reinforcer. 
However, this raises the difficult question of how many operant 
responses under an FR schedule are required to convincingly 
tap into appetitive processes. For example, it is not clear 
whether an FR2 schedule measures a psychological process 
different from that measured by FR1. In contrast, responses 
under a PR schedule of reinforcement are unequivocally 
appetitive. Another important difference between a PR 
schedule and an FR1 schedule is that a PR schedule produces 
very high work demand. Under a PR schedule, obtaining each 
successive drug injection requires an increasing number of 
operant responses, until the subject ceases drug self-
administration. The number of operant responses performed to 
obtain the last drug infusion is termed the breakpoint and it is 
used to infer the motivation to obtain drug (Hodos, 
1961 and Richardson and Roberts, 1996). Thus, the PR 
schedule queries an animal about how much physical work it is 
willing to emit to obtain a reinforcer, and the answer is used as 
an index of the motivation to procure that reinforcer. Schedules 
such as PR lend themselves to standard operant interpretation 
and can be used to assess motivational issues under conditions 
of very high work demand (Roberts et al., 2013). Such 
schedules can be used with operant theory or behavioural 
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economics to infer changes in the motivation to seek drugs or 
continue a binge. 
A substantial body of evidence has accumulated which shows 
that drug consumption and appetitive responding for drugs 
have partially distinct neurobiological substrates and are 
differentially affected by a wide variety of manipulations. For 
example, drug consumption under conditions of very low work 
demand (under an FR1 schedule) and appetitive responding for 
drugs under conditions of high work demand (under a PR 
schedule) are differentially affected by neurotoxic lesions (Loh 
and Roberts, 1990, Roberts, 1989 and Roberts et al., 1994), 
pharmacological pretreatments (Brebner et al., 
2000 and Espana et al., 2010), the estrous cycle (Roberts et al., 
1989) and diurnal rhythms (Bass et al., 2010 and Fitch and 
Roberts, 1993). Note that while human addicts do not self-
administer drug on PR schedules per se, they are willing to 
suffer significant escalations in both price and work output in 
order to obtain drug. In addition, PR tests in animal models are 
essential because they provide tools to assess how various 
patterns of drug taking influence the motivation for further use. 
In the following sections, we will use the rough distinction 
between FR1 schedules of reinforcement versus other 
schedules with higher response requirements such as the PR 
procedure to discuss the effect of pharmacokinetic variables on 
drug taking versus drug seeking, respectively. 
3.3. Pharmacokinetic variables influence drug-taking 
(consummatory) behaviour 
3.3.1. Drug-taking behaviour during limited daily access to 
drug 
Pharmacokinetic variables such as dose and speed of drug onset 
have minor effects on rate of drug intake in the acute stage—
but in situations that would be expected to promote a change in 
the pattern of intake, these variables are critical. First, it is 
important to recognize that cocaine self-administration can be 
remarkably stable. Although drug self-administration during 
daily 1–3 h, FR1 sessions can produce psychomotor and 
neurochemical sensitization, and sensitization-related 
neuroadaptations can promote increased drug intake (Hooks et 
al., 1994, Lorrain et al., 2000 and Phillips and Di Ciano, 1996), 
cocaine intake during short daily sessions is tightly regulated 
and changes little over time (Ahmed et al., 2002, Ahmed and 
Koob, 1998, Deroche-Gamonet et al., 2004, Knackstedt and 
Kalivas, 2007 and Mantsch et al., 2004). Under these stable 
conditions, manipulations of dose generally have little effect on 
intake within or between sessions. For instance, if cocaine dose 
is manipulated during limited FR1 self-administration sessions, 
rats will self-administer lower doses more frequently than 
higher doses (Pickens and Thompson, 1968 and Wilson et al., 
1971), but hourly intake will typically remain stable both 
within a session and over days. Fig. 4 shows the cocaine dose–
response relationship under these conditions, depicted as the 
responses during a 2-h session. The figure illustrates that 
cocaine intake is held constant across a 10-fold range of doses 
(41–421 µg/infusion). Fig. 5a shows fluctuations in brain 
cocaine levels in an animal self-administering 500 µg/infusion 
under these conditions, estimated using a mathematical model 
(Ahmed and Koob, 2005, Nicola and Deadwyler, 2000, Pan et 
al., 1991 and Wise et al., 1995). The event record in Fig. 5a 
shows that there is a typical “loading phase” at the beginning of 
the session—a collection of several injections that produce a 
rapid rise in brain levels followed by an extremely regular 
pattern of responding that results in brain cocaine levels being 
maintained within a narrow range. Under these conditions, both 
hourly cocaine intake and intake over days remain relatively 
constant across a wide dose range. It is not clear why intake 
under these conditions generally does not change over time, or 
why some conditions that can produce psychomotor and 
neurochemical sensitization produce unchanging levels of drug 
intake. Just as the expression of behavioural sensitization is 
observed more readily following a period of drug withdrawal, it 
is possible that following limited daily self-administration 
sessions, an increase in drug intake might be observed after a 
sufficiently long abstinence period. However, it has been 
shown that in animals with a history of self-administering 
cocaine during short daily sessions, drug intake remains stable 
even following one month of forced abstinence (Ahmed and 
Koob, 1998 and Hollander and Carelli, 2005). Thus, escalation 
of drug intake is often not observed following short daily self-
administration sessions, even though the same conditions can 
evoke psychomotor and neurochemical sensitization. Based on 
such evidence, some authors have concluded that psychomotor 
sensitization should not be used as a marker for the transition to 
increased drug use (Ahmed and Cador, 2006), while others 
maintain that psychomotor sensitization and changes in drug 
use are more readily linked under conditions of extended access 
to drug (Ferrario et al., 2005). 
 
Fig. 4. The effect of manipulating dose on rate of responding (A) and 
total intake (B) for a group of rats self-administering intravenous 
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injections of various unit doses of cocaine during daily two-hour 
sessions. Panel A illustrates an inverted ‘U’ shaped curve, and at the 
high end of this curve, responding decreases as dose increases. Panel 
B illustrates that over the dose range characterized by a decrease in the 
number of injections (41–421 µg/infusion, framed within dotted lines), 
intake is relatively constant. Data are mean ± SEM. Adapted from 
Oleson and Roberts (2009). 
 
Fig. 5. The pattern of intake and modelled cocaine levels in the brain 
for representative animals tested during three distinct self-
administration procedures. Each panel shows the modelled brain levels 
of cocaine corresponding to the pattern of intake indicated by the 
event record. Curves were generated using a model developed by Pan 
et al. (1991). Pan et al. (1991) used microdialysis to measure brain 
concentrations of cocaine injected intravenously. The relevant 
pharmacokinetic parameters were then estimated by fitting a two-
compartment open model to the data using nonlinear regression. The 
equations used by the model and the parameter estimates are provided 
in Pan et al. (1991). ShA, 2-h, Short Access session 
(0.75 mg/kg/infusion, with a 20-s time out period). LgA, 6-h, Long 
Access session (0.75 mg/kg/infusion, with a 20-s time out period). 
IntA, 6-h, Intermittent Access session (12 discrete 5-min trials 
separated by a 25-min inter-trial-interval; 0.375 mg/kg/infusion). Note 
that in the intermittent access sessions, no time out was imposed, 
allowing animals to self-administer multiple injections within a few 
seconds. Adapted from Zimmer et al. (2012). 
During time-limited (1–3 h), FR1 sessions, the speed of drug 
delivery has minor effects on drug intake acutely, but it can 
significantly influence change in drug use over time. Some 
studies show that rapid i.v. injections of cocaine or nicotine 
lead to greater drug intake within each time-limited session 
(Kato et al., 1987, Schindler et al., 2011 and Schindler et al., 
2009), other studies do not show this effect (Crombag et al., 
2008, Minogianis et al., 2013, Sorge and Clarke, 
2009 and Wakabayashi et al., 2010). This suggested that the 
speed of drug onset might not critically influence drug intake 
during short, FR1 sessions. However, a more recent study 
suggests that this lack of effect might be restricted to the initial 
stages of drug self-administration (the first 3–4 sessions 
following acquisition of the drug self-administration task). 
Bouayad-Gervais et al. (2014) showed that, consistent with 
prior studies (Crombag et al., 2008, Minogianis et al., 
2013 and Wakabayashi et al., 2010), varying the speed of i.v. 
cocaine injection (5 or 90 s) has no effect on intake during the 
first 3–4 self-administration sessions. However, Bouayad-
Gervais et al. (2014) bring new data to this literature by 
showing that beyond these initial sessions, faster i.v. cocaine 
injections led to greater drug intake than slower cocaine 
injections. Group differences emerged because the rats given 
access to slower cocaine injections decreased their intake over 
days. In contrast, the rats given access to more rapid injections 
maintained stable drug intake over test days. The latter finding 
is consistent with the great majority of studies using short daily 
self-administration sessions (1–3 h), where drug is delivered at 
speeds comparable to 5 s, and intake remains stable over time. 
It remains to be determined why the self-administration of 
sustained cocaine infusions decreases over repeated test days. 
As research on this issue unfolds, the findings of Bouayad-
Gervais et al. (2014) support the idea that variation in the speed 
of drug delivery evokes neuroadaptations over time, leading to 
differences in drug intake with repeated drug exposure. The 
next section will show that the effect of pharmacokinetic 
variables including the speed of drug onset on drug intake over 
days is even more dramatic in animals given longer daily 
sessions (long-access sessions; LgA)—a procedure designed to 
promote addiction-related neuroplasticity. 
3.3.2. Drug-taking behaviour during extended daily access to 
drug 
“Escalation of drug intake” has become a major focus in the 
cocaine self-administration literature and this phenomenon also 
serves to illustrate the importance of pharmacokinetic variables 
in behavioural plasticity. Here we will show that the capacity 
for one day of cocaine intake to influence the rate of intake on 
the next day is facilitated by the use of large doses, intermittent 
drug access, and doses injected quickly. Lengthening the daily 
session length, a procedure termed long access (LgA), has been 
shown to increase the rate of within-session intake by about 
40–70% over 2–3 weeks (Ahmed and Koob, 1998, Ahmed and 
Koob, 1999, Ben-Shahar et al., 2004, Knackstedt and Kalivas, 
2007 and Wee et al., 2008). The LgA procedure is a powerful 
animal model because if one wishes to model addiction in 
laboratory animals, one expects these animals to change their 
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drug-taking behaviour over time. In the LgA model, escalation 
of drug intake is modulated by several variables. For instance, 
rats can show significant inter-individual variability in the 
propensity to escalate their cocaine intake (Deroche-Gamonet 
et al., 2004 and Wakabayashi et al., 2010). Pharmacokinetic 
variables also play a role. For instance, using nicotine, it has 
been shown that when periods of drug self-administration are 
interspersed with periods of forced abstinence, this promotes an 
escalation in nicotine intake (Cohen et al., 2012). Furthermore, 
escalation might be more likely at high doses of cocaine. Dose–
response curves are not widely studied in the literature on the 
escalation of cocaine intake. A notable exception is Mantsch et 
al. (2004), who showed that escalation occurs earlier at higher 
doses (2 versus 0.5 mg/kg/injection). This is in line with a 
number of studies that have failed to see escalation of cocaine 
intake at lower drug doses (0.25–0.6 mg/kg/injection) (Ferrario 
and Robinson, 2007, Kippin et al., 2006, Mantsch et al., 
2004 and Minogianis et al., 2013). Escalation is also facilitated 
by a rapid speed of cocaine onset. Studies showing that 
prolonged daily access to drug can promote the escalation of 
drug intake use rapid i.v. injections of drug (Ahmed and Koob, 
1998, Ahmed and Koob, 1999, Ben-Shahar et al., 2004, 
Knackstedt and Kalivas, 2007 and Wee et al., 2008). This 
prompted us and others to ask whether the speed of drug 
delivery plays a role in the propensity to escalate drug 
consumption. Work on this issue showed that when daily 
access to cocaine is increased from 1 to 6 h, rats given access to 
rapid (5–45 s) versus slower (90 s) injections of cocaine take 
more drug and are also more likely to escalate their 
consumption over days (Bouayad-Gervais et al., 2014, 
Minogianis et al., 2013 and Wakabayashi et al., 2010). Fig. 6 
illustrates this effect. Such effects are observed in spite of the 
fact that in these latter studies, all rats had equal opportunity to 
take cocaine (one injection was available every 90 s). Thus, 
extended access to drug by itself is not sufficient to promote 
escalated drug use, and the speed of drug onset is decisive in 
producing this behavioural change. In summary, in agreement 
with clinical observations and the literature on psychomotor 
sensitization, dose, the intermittency of drug use, and the speed 
of drug onset are key determinants of behavioural change in the 
LgA model of drug self-administration. This serves to highlight 
the role of pharmacokinetic factors in the plastic changes 
associated with the addiction process. 
 
Fig. 6. In rats given extended daily access to cocaine, only those self-
administering rapid cocaine injections escalate their drug intake over 
time. Panel A shows cocaine intake in the first hour of the 6-h session, 
in rats self-administering rapid intravenous cocaine injections 
(delivered over 5 s) and in rats self-administering slower injections 
(90 s). Panel B shows total cocaine intake during each 6-h session in 
the same animals. Rats received three short-access sessions (ShA; 
1 h/session) prior to the 10 long-access sessions (LgA; 6 h/session). In 
(A), ‘ShA’ shows the average number of infusions taken over these 
three sessions. Data represent mean ± SEM. N = 12–13/group. s, 
second. # p < 0.05 compared to the 90-s rats. * p < 0.05 compared to 
the 1st session of LgA in 5-s rats. Adapted from Bouayad-Gervais et 
al. (2014). 
3.4. Pharmacokinetic variables influence drug-seeking 
(appetitive) behaviour 
A key question in addiction is how specific patterns of drug 
taking predispose an individual to further drug use. This is a 
critical question to address if one wishes to understand why 
some drug users maintain control over their drug use, while 
others develop excessive and pathological patterns of drug use, 
and ultimately addiction. Accordingly, there is now a trend in 
the literature to assess how cocaine consumption affects the 
appetitive response – or put another way – how patterns of 
consumption subsequently affect an animal's motivation to seek 
and use drugs. In the next sections, we will review some 
procedures that affect appetitive responding for drug. These 
include the long access (LgA), discrete trials (DT), and 
progressive ratio training (PR) procedures. Data from these 
models hint at the importance of the intermittency of drug use 
and speed of drug onset in determining the subsequent 
motivation to seek and take drug. Finally, we will review 
findings from a new model of drug self-administration 
behaviour that powerfully illustrates how intermittent ‘spikes’ 
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in brain levels of cocaine can be more effective than high and 
sustained levels in determining the subsequent motivation to 
seek and take the drug. 
3.4.1. The long-access model 
While some inconsistencies exist, there are numerous reports of 
drug self-administration under LgA conditions changing the 
susceptibility to relapse, drug seeking in spite of punishment, 
and, responding for drug under a PR schedule of reinforcement. 
For instance, compared to rats given limited daily access to 
cocaine, rats given LgA sessions are more vulnerable to drug-
primed reinstatement of previously extinguished responding for 
cocaine (Ahmed and Cador, 2006, Ahmed and Koob, 1998, 
Knackstedt and Kalivas, 2007 and Mantsch et al., 2004). LgA 
rats also show greater responding for cocaine in spite of 
punishment (footshock) (Vanderschuren and Everitt, 2004), 
and also reach higher breakpoints for cocaine under progressive 
ratio conditions (Hao et al., 2010, Paterson and Markou, 
2003 and Wee et al., 2008; note however that this latter effect 
is not always observed, Bouayad-Gervais et al., 2014, Liu et 
al., 2005a and Oleson and Roberts, 2009). 
While testing of pharmacokinetic variables with the LgA model 
has been limited, the data again support the idea that 
intermittent drug access, high doses and a rapid speed of drug 
onset are critical to the ability of extended self-administration 
sessions to influence appetitive responding. The data further 
show that there are strong parallels in the effects of 
pharmacokinetic variables on consummatory and appetitive 
behaviours. For instance, when access to cocaine is given 
intermittently by interspersing LgA sessions with periods of 
forced abstinence, this promotes the development of increased 
motivation for cocaine, as assessed using a progressive ratio 
schedule of cocaine reinforcement (Morgan and Roberts, 
2004). The ability of LgA sessions to promote cocaine-primed 
reinstatement of drug-seeking behaviour is also facilitated by 
the use of high doses during the LgA phase (Mantsch et al., 
2004). Finally, when the speed of i.v. drug injection is varied 
during LgA sessions, rats allowed to self-administer rapid 
cocaine injections (5 versus 90 s) subsequently show increased 
motivation to obtain the drug (Bouayad-Gervais et al., 
2014 and Minogianis et al., 2013). This effect is illustrated in 
Fig. 7. Rats with a history of taking rapid cocaine injections are 
also more vulnerable to drug-primed reinstatement of cocaine-
seeking behaviour after a long period of forced abstinence (45 
days; Wakabayashi et al., 2010). The ability of rapidly 
administered cocaine to increase motivation to obtain drug and 
the susceptibility to reinstatement is not just a consequence of 
the amount of drug previously consumed. Even when the rats 
self-administering rapid cocaine injections take the same 
amount as rats self-administering slower injections, the former 
show greater motivation for drug and a more persistent 
vulnerability to reinstatement (Bouayad-Gervais et al., 2014, 
Minogianis et al., 2013 and Wakabayashi et al., 2010). Thus, 
how much, how often and how fast a drug reaches the brain all 
determine the neuroplasticity that underlies changes in 
appetitive behaviours characteristic of addiction. 
 
Fig. 7. The self-administration of rapid cocaine injections in the past 
leads to increased motivation to take the drug in the future. The figure 
illustrates responding for intravenous cocaine injections under a 
progressive ratio schedule of reinforcement in animals that have 
previously self-administered rapid (delivered over 5 s) or more 
sustained (90 s) cocaine infusions. Corresponding ratios are included. 
Panel A illustrates that rats in the 5-s group show an increased 
motivation to take cocaine, across a range of doses during progressive 
ratio testing. In (A), cocaine was delivered over 5 s for the 5-s group, 
and over 90 s for the 90-s group. Panel B shows that rats in the 5-s 
group also show an increased motivation to take cocaine regardless of 
drug injection speed during progressive ratio testing. Data represent 
mean ± SEM. N = 11–16/group. s, second. PR 5 s, cocaine was 
delivered over 5 s during progressive ratio testing. PR 90 s, cocaine 
was delivered over 90 s during progressive ratio testing. # p < 0.0001 
and * p < 0.05 compared to the 90-s rats. Adapted from Minogianis et 
al. (2013). 
What accounts for the ability of LgA self-administration 
sessions to influence subsequent appetitive responding for 
drug? The early literature suggested that increased appetitive 
responding for drug results from elevated amounts of drug 
consumed (i.e., area under the curve). Some suggest the 
existence of “…a threshold level that can readily establish and 
sustain addiction” (Benowitz and Henningfield, 1994), and that 
“…below this critical level of exposure, there would be no 
drug-induced neuropathological changes, and drug use would 
remain under control, at least in the majority of drug-exposed 
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animals” (Ahmed, 2012). Said differently, to induce addiction, 
“more is better” and sustained levels are important. This is a 
reasonable assumption given that compared to ShA sessions, 
LgA sessions are much more effective in promoting future 
appetitive responding for drug, and an obvious difference 
between the two procedures is the level of prior drug exposure 
(modelled in Fig. 5). If this is correct, then elevated brain levels 
in the past should be sufficient to enhance the motivation to 
obtain drug in the future. Another possibility is that the number 
of injections is important. That is, that the frequency at which 
brain levels of drug rise and fall might influence future patterns 
of drug use. The fact that dose and speed of injection are 
critical factors suggests that the size and speed of the “spike” in 
cocaine levels may be important. However, it is difficult to test 
the relative contributions of area under the curve versus spiking 
brain levels in conventional LgA/ShA models. The length of 
the session and the number of injections will always be 
confounded. Whether ‘spikes’ are necessary and/or sufficient to 
drive the important behavioural and neurochemical changes 
associated with the addiction process needs to be tested using 
different experimental procedures. As will be detailed further 
below, recent work tests this directly. 
3.4.2. The discrete trials model 
Discrete trials procedures (DT) were a first attempt in 
determining whether an increase in the motivation to obtain 
drug could be seen in animals with a history of intermittent 
rather than continuous drug access during each self-
administration session. The DT procedure allows animals to 
self-administer 24 h a day, but manipulates hourly drug intake. 
Animals have the opportunity to self-administer one injection 
and must then wait until the next trial within the hour for 
another opportunity. For example, DT4 involves giving 4 
opportunities to take a single drug injection per hour. Under 
this schedule, rats tend to take an injection during every trial 
for the first 24 h and then settle into a regular daily pattern of 
intake, with drug taking restricted to the dark phase of the 
activity cycle (Roberts et al., 2002). Interestingly, self-
administration on a DT4 protocol for 10 days increases 
breakpoints under a PR schedule of reinforcement, and this 
increase depends on an abstinence period. If animals are tested 
immediately after 10 days of DT4 there are no changes in 
breakpoints (Morgan et al., 2002 and Morgan et al., 2005). But 
if a seven-day abstinence period is introduced, then 
sensitization of breakpoints is observed (Morgan and Roberts, 
2004). The DT procedure thus illustrates that high and 
sustained brain levels of drug (as achieved with a conventional 
LgA session) are not a necessary condition to enhance the 
subsequent motivation for drug. The DT4 model also 
demonstrates that intermittent drug exposure followed by an 
abstinence period facilitates the development of sensitization to 
the motivational effects of cocaine. This concords with the 
literature on psychomotor sensitization, where intermittent drug 
exposure and a withdrawal period can be decisive (Downs and 
Eddy, 1932, Post, 1980, Post and Rose, 1976, Reith et al., 
1987, Robinson and Becker, 1986 and Stewart and Badiani, 
1993). The DT model does have its limits. It can be argued that 
the parameters are arbitrary and restrictive, and that the daily 
pattern does not resemble the way human addicts take cocaine. 
Still, it is an important demonstration that an intermittent 
pattern of cocaine intake evokes sensitization of appetitive 
responding for cocaine. 
3.4.3. Daily testing under a progressive ratio schedule of 
cocaine reinforcement 
Daily testing on a PR schedule of drug reinforcement is another 
procedure illustrating that sustained brain levels of drug are not 
a necessary condition to augment subsequent appetitive 
responding for drug. With daily testing, breakpoints maintained 
by cocaine escalate to very high levels over time (Liu et al., 
2005b). Intriguingly, very low levels of prior cocaine intake 
result in rapid sensitization of breakpoints, whereas high levels 
of prior intake suppress the development of this sensitization 
(Morgan et al., 2006). Daily testing under a PR schedule of 
drug reinforcement was not intended as a model of human drug 
taking. However, the observation that breakpoints escalate over 
time – with about the same drug exposure as ShA – suggests 
that something interesting is going on. One possibility is that 
the schedule imposes a constraint on intake. It takes time to 
complete the high response ratios and brain levels of drug fall 
in between each injection. As such, the PR schedule would 
promote greater ‘spiking’ from lower brain levels of drug than 
the LgA procedure. Are these ‘spikes’ in brain drug levels 
important? Indeed they are. The susceptibility to escalate 
breakpoints for cocaine is determined by dose and the speed of 
drug onset (Liu et al., 2005b). When rats were given access to 
cocaine injections delivered i.v. over 5, 25 or 50 s, only rats 
taking 5-s injections showed an escalation in breakpoints. 
Similarly, only larger unit injection doses produced escalation 
of breakpoints (Liu et al., 2005b). These findings suggest that a 
rapid rise from low to high brain levels of drug is an important 
determinant of the future motivation to seek and take cocaine. 
3.4.4. A new model: Intermittent access to drug during a long-
access session 
The protocols reviewed above suggest that rapidly rising and 
intermittent spikes in brain levels of cocaine might be decisive 
in predicting subsequent appetitive responding for drug, but 
this awaited formal investigation. Recently, one of the authors 
of the present review (D.C.S.R.) set about testing whether fast, 
“spiking” levels might drive the change in appetitive 
responding. To this end, a new model of cocaine self-
administration was developed involving intermittent, within-
session access to drug (Zimmer et al., 2012). The recent survey 
data in experienced cocaine users that we described above 
provided additional impetus to develop this model. These 
survey data suggested that experienced cocaine users likely do 
not maintain high brain levels of the drug, but might instead 
voluntarily achieve marked reductions in brain levels, which 
then rapidly rise with each drug self-administration (Beveridge 
et al., 2012). The intermittent access (IntA) procedure models 
this by limiting cocaine availability during a 6-h session to 
twelve 5-min discrete trials separated by 25-min timeout 
periods. Brain cocaine levels cannot be maintained; instead the 
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animals experience twelve rapidly rising spikes in cocaine 
levels during each session. Thus the IntA protocol tests the 
effect of a history of cocaine ‘spikes’ on the motivation to self-
administer the drug later on, and it also allows for a direct test 
of the importance of ‘spiking’ versus sustained cocaine levels 
(Zimmer et al., 2012). To this end, IntA rats were compared to 
LgA rats. Predictably, the LgA group took much more cocaine 
than the IntA group. In addition, pharmacokinetic modelling 
suggested that LgA sessions would produce continuously high 
brain cocaine levels while IntA sessions would produce 
repeated, fast-rising spikes in brain cocaine levels (modelled in 
Fig. 5). Remarkably, in spite of being exposed to significantly 
less cocaine, the IntA rats were more motivated to self-
administer the drug in the future (Zimmer et al., 2012). This is 
consistent with other findings showing that even extremely 
high levels of cocaine intake are not sufficient on their own to 
increase the subsequent motivation to take the drug (Roberts et 
al., 2002). Such findings are a challenge to the belief that 
simply maintaining high levels of drug intake is sufficient to 
develop an addicted phenotype. Instead, it appears that when it 
comes to producing an increase in the motivation to obtain 
drug, ‘how often’ drug is taken can be more important than 
‘how much’. In support of this idea, recent work in rats shows 
that the early occurrence of a burst-like pattern of cocaine 
intake is a behavioural marker of vulnerability to compulsive 
drug use (Belin et al., 2009). Amongst a group of rats allowed 
to self-administer cocaine, the subset that spontaneously and 
rapidly developed a high-frequency pattern of intake 
(spontaneous intake of >5 infusions in less than 5 min) was 
particularly vulnerable to develop addiction-like symptoms. 
These symptoms included increased motivation to obtain drug, 
persistence of drug-seeking behaviour in spite of signalled 
unavailability of cocaine and self-administration in spite of 
physical punishment. Importantly, the rats that developed a 
burst-like pattern of cocaine use did not differ from the other 
rats with respect to cumulative cocaine intake. Similarly, by 
dividing rats into two groups based on their spontaneous, self-
imposed interval between cocaine infusions, Martin-Garcia et 
al. (2014) found that rats showing high-frequency cocaine self-
administration are more vulnerable to cocaine-primed 
reinstatement of drug-seeking behaviour relative to rats with 
low-frequency cocaine intake—in spite of equivalent levels of 
prior drug intake. Together, these findings suggest that an 
intermittent pattern of use, more than the amount of drug used, 
governs the susceptibility to increased drug use. 
A key question is how the IntA procedure maps onto what we 
know about human cocaine intake. As discussed, new work 
suggests that experienced cocaine users take cocaine in a 
pattern different than previously thought, achieving intermittent 
and rapidly rising brain levels of the drug, rather than 
maintaining high and sustained levels (Beveridge et al., 2012). 
Even in between bouts of drug self-administration, human 
addicts likely do not have relatively continuous access to drug, 
several hours a day, for weeks/months on end (as modelled by 
the LgA procedure). Due to the interaction of several factors, 
some willed by the user, others not (jail time, lack of money, 
etc) drug intake, particularly cocaine intake, is intermittent, 
both within and between bouts of intoxication. Given this, 
understanding what happens to the brain when cocaine intake is 
intermittent is important. By modelling this in laboratory 
animals, the IntA procedure clearly shows that in producing 
change in the motivation to take drug over time, sustained brain 
levels of drug are not necessary, and spiking levels look to be 
the prime determinant. This is consistent with clinical 
observations, and also corroborated by evidence from studies 
using the more traditional LgA, DT and daily PR testing 
procedures, where a rapid speed of drug onset and high doses 
are critical for the development of behavioural change. 
3.5. Pharmacokinetics determine the neuroplasticity evoked by 
drugs 
Pharmacokinetic variables determine the impact drugs have on 
the brain. Everything that we have described for behaviour 
above has important parallels with neurochemical and 
neurobiological findings. A first series of studies showed that 
the speed of drug onset determines drug-induced effects on 
gene regulation. Rats with a history of taking rapid cocaine 
injections during LgA sessions show desensitization of 
cocaine-evoked Fos expression in the nucleus accumbens, 
while rats exposed to slower injections do not (Wakabayashi et 
al., 2010). This is reminiscent of findings using experimenter-
administered nicotine, showing that rats that were previously 
treated with rapid i.v. injections of the drug (5 versus 90 s) 
show greater desensitization of nicotine-evoked c-fos and arc 
mRNA expression in the nucleus accumbens shell and caudate-
putamen (Samaha et al., 2005). The functional significance of 
these changes is unknown. However, an interesting hypothesis 
is that the time-course of drug-induced plasticity in gene 
regulation might vary as a function of the speed of drug onset 
(Samaha et al., 2005). Variation in the speed of i.v. cocaine 
delivery also alters the brain expression of the neurotrophin, 
brain-derived neurotrophic factor (BDNF) and of its receptor, 
tropomyosin receptor kinase B (TrkB) (Bouayad-Gervais et al., 
2014). Chronic exposure to cocaine and other psychostimulant 
drugs regulates brain BDNF mRNA and protein levels (Asan, 
1997, Fumagalli et al., 2007, Grimm et al., 2003 and Im et al., 
2010), and BDNF-mediated signalling specifically in midbrain 
and corticostriatal regions mediates drug-seeking and drug-
taking behaviours (Graham et al., 2007, Graham et al., 2009, 
Im et al., 2010 and Unterwald et al., 2001). In rats given LgA 
session, only those taking rapid cocaine injections (5 versus 
90 s) show altered BDNF and TrkB mRNA levels in 
corticostriatal structures (caudate-putamen, orbitofrontal, 
frontal and parietal cortices, but not the nucleus accumbens or 
medial prefrontal cortex) (Bouayad-Gervais et al., 2014). At 
present, it remains unknown how the mRNA changes might 
translate to protein changes and whether increased regulation of 
BDNF and TrkB in corticostriatal nuclei plays a causal role in 
the behavioural effects of rapid cocaine delivery. Dopamine D2 
receptor changes have also been reported in rats with a history 
of self-administering rapid versus more sustained cocaine 
injections during LgA sessions. Following 2 weeks of 
withdrawal from cocaine, rats with a history of taking slow 
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cocaine injections have decreased D2 receptor levels in the 
caudate-putamen, and D2 receptors with greater agonist affinity 
(Minogianis et al., 2013). As with the BDNF–TrkB mRNA 
findings, additional work is needed to determine how the 
observed D2 receptor changes might contribute to the 
behavioural effects of the speed of cocaine delivery. Future 
studies can determine whether the D2-receptor related changes 
modify striatal signalling in ways that protect from excessive 
motivation to take cocaine (Minogianis et al., 2013). 
How often drug levels rise and fall within a bout of drug self-
administration is also a prime determinant of drug effects on 
the brain. The intake of cocaine at short (2 min) rather than 
longer (6 min) intervals within each self-administration session 
preferentially increases c-Fos protein levels in the prelimbic 
and infralimbic cortices, the nucleus accumbens shell and core 
and the basolateral nucleus of the amygdala (Martin-Garcia et 
al., 2014). Optogenetic manipulations also show that neuronal 
activity within the prelimbic cortex regulates cocaine-seeking 
and -taking behaviours only in animals allowed to self-
administer cocaine at short inter-infusion intervals (Martin-
Garcia et al., 2014). This suggests that cocaine intake at short 
inter-infusion intervals promotes the ability of the prelimbic 
cortex to control drug use. Finally, Calipari et al., 
2013 and Calipari et al., 2014 have assessed the influence of 
intermittent spikes in brain cocaine levels on the dopamine 
transporter (DAT). They compared LgA rats to IntA rats. IntA 
rats developed sensitization to the ability of cocaine, 
methylphenidate and methamphetamine to inhibit the DAT 
within the nucleus accumbens, while LgA rats developed 
tolerance to cocaine's effects at the transporter (Calipari et al., 
2013 and Calipari et al., 2014). This is in agreement with 
studies using experimenter-administered drug and showing that 
intermittent access promotes sensitization of cocaine's effects 
on dopamine reuptake, while continuous access promotes 
tolerance (Izenwasser and Cox, 1990 and Izenwasser and Cox, 
1992). The findings of Calipari et al., 2013 and Calipari et al., 
2014 also concord with recent work showing that LgA rats 
show decreased phasic dopamine levels in the nucleus 
accumbens core (Willuhn et al., 2014). 
4. Why is it useful to study the temporal dynamics of drug 
delivery as an active principle in addiction? 
In attempting to reduce the enormous impact of drug addiction 
on health and society, the first step is to understand the factors 
that can modulate the development of the disorder. As the 
literature reviewed above demonstrates, in determining the 
effects of drugs on brain and behaviour, the dynamics of drug 
delivery are not just secondary to achieved dose or to the 
crossing of certain threshold levels of drug exposure. Instead, 
they determine brain and behaviour changes that are relevant to 
the addiction process. A growing literature suggests that, in 
keeping with clinical observations, animals that take drugs like 
cocaine in a pattern that produces rapidly rising and 
intermittent ‘spikes’ in brain levels of drug more readily 
develop an addiction phenotype. Thus, evidence is emerging to 
help us better understand what routes and patterns of drug 
administration are the most addictive. This information has 
tremendous implications. First, it can be used to identify 
vulnerable drug users most susceptible to progress towards 
addiction, allowing early intervention strategies to be 
implemented. Second, this work has implications for new 
treatment avenues. Pharmacokinetic principles are already 
exploited to treat addiction to some drugs (nicotine patch/gum 
versus smoking a cigarette; methadone versus heroin). 
Pharmacokinetic principles might also be used in the 
development of agents to treat addiction to drugs like cocaine. 
If spiking brain levels of drug do indeed contribute to 
addiction, pharmacological ways of flattening these spikes can 
be envisioned. Finally, upstream of this, data from the basic 
science literature can be used to educate the public and 
influence choices not only about whether to take drugs, but 
how. Scientists have long known that pharmacokinetics matter, 
the layperson might not. The public would benefit from 
education about the consequences of using certain routes, 
patterns of drug use and drug formulations. 
5. Where do we go from here? 
Great strides have been made in understanding the importance 
of pharmacokinetic factors in drug addiction, but important 
data are still missing. It is known that pharmacokinetics 
influence the behavioural response to drugs and some 
neurobiological correlates have been reported. However, the 
neurobiological findings remain largely correlational. There is 
little evidence on how specific brain changes might play a 
causal role in the ability of the speed of drug onset or the 
intermittency of drug use to influence behaviour. In parallel, we 
know little about what brain levels of drug look like when 
experienced drug users are given control over drug 
pharmacokinetics (e.g., dose, intermittency of dosing, speed of 
drug onset). Such information would be critical for the design 
of both representative brain imaging studies in humans and 
drug self-administration experiments in laboratory animals. 
6. Concluding remarks 
If we as drug addiction researchers ignore pharmacokinetics, 
we do so at our peril. There is strong evidence that chronic 
exposure to intermittent and rapidly rising brain levels of drug 
(cocaine in particular) promote an escalation in consummatory 
and appetitive responding for drug. This has notable parallels 
with the extensive literature on psychomotor sensitization, 
where there is agreement that intermittency of drug exposure 
and abstinence periods are key (Post, 1980 and Robinson and 
Becker, 1986). The ability of rapidly rising brain levels of drug 
to facilitate excessive patterns of drug use is associated with 
changes in gene regulation, dopamine neurochemistry and cell 
function that are thought to be important in the addiction 
process. In several instances, such rapidly spiking brain levels 
of drug were directly compared with high and sustained brain 
levels (e.g., IntA versus LgA). This work reveals that the two 
pharmacokinetic profiles produce different outcomes and that 
out of the two, drug ‘spikes’ appears to push the addiction 
process forward more effectively. This has profound 
implications for better understanding the neuroadaptations that 
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are critical for addiction. There is a great amount of data on the 
ability of LgA procedures to promote changes in brain and 
behaviour. This model is currently dominating the literature on 
drug self-administration in animals (even in our own past work 
Bouayad-Gervais et al., 2014 and Minogianis et al., 2013), and 
it has shed important new light on how extensive exposure to 
sustained and high levels of drug change brain and behaviour. 
LgA is widely used because many would say that it has face 
validity since it produces escalation from more modest drug 
intake to binge use. However, as argued above, it is unlikely 
that human cocaine addicts have relatively free access to 
cocaine several hours a day, for days on end, enabling them to 
maintain high and sustained brain levels of drug. Rather, they 
might voluntarily achieve intermittently rising brain levels of 
drug during a bout of intoxication (Beveridge et al., 2012), and 
also use intermittently over time (Cohen and Sas, 
1994 and O’Brien, 2001). Moreover, work in animals shows 
that continuously high versus intermittently high brain levels of 
cocaine can produce opposite effects on DA system function 
for example (Calipari et al., 2013 and Calipari et al., 2014). 
This deserves research attention, as we want to be sure which 
model more closely captures the way humans take drugs. The 
temporal pattern of drug use is of tremendous importance in 
addiction, particularly cocaine addiction, and this should be 
reflected in the animal models we use to study addiction in the 
laboratory. 
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